Main Logo
  • About Us
    • Our Philosophy
    • The Industry and Us
  • Our Strategy
    • Our Technology
    • Key Applications
    • Clinical Programs
    • Preclinical Programs
    • Pipeline
    • Our Partnerships
  • Our Team
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Media / Science Center
  • Contact Us
  • Investors

Press Releases

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
    • In The News
    • Videos
  • Events & Presentations
    • Events
    • Presentations
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Filings & Financials
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Management Team
  • Investor Resources
    • Contacts
    • Email Alerts
    • FAQs
    • Investor Fact Sheet
  • News

  • Press Releases
  • Email Alerts
  • In The News
  • Videos
Oct 11, 2023 8:15am EDT

Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit

Oct 03, 2023 8:15am EDT

Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023

Sep 26, 2023 8:15am EDT

Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study

Sep 19, 2023 8:15am EDT

Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023

Sep 14, 2023 8:15am EDT

Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies

Sep 07, 2023 8:15am EDT

Ensysce Presents "A New Generation of Safer Pain Treatments"

Sep 05, 2023 8:15am EDT

Ensysce Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023 8:15am EDT

Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium

Aug 11, 2023 8:00am EDT

Ensysce Biosciences Reports Second Quarter 2023 Financial Results

Aug 08, 2023 8:15am EDT

Ensysce Biosciences Announces IRB Approval of Key Study Protocol

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 20
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Main Logo

Biotech company committed to stemming the prescription drug abuse epidemic.

Our proprietary prodrug technologies are designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription drug abuse.

About Us

  • Our philosophy
  • The Industry and Us

Our strategy

  • Our Technology
  • Key Applications
  • Clinical Programs
  • Preclinical Programs
  • Pipeline
  • Our Partnerships

Our Team

  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Contact Us

Investors

Follow Ensysce on social media:

  • /company/Ensyscebio
  • @Ensyscebio
  • /Ensyscebio